

Supplementary Materials, Annex Table 6A. Progression-free survival based on tumor site in grade 1 and 2 NENs.

Tumor site	N/n	Median PFS (months)	95% CI
pNENs	154/70	23.4	18.2-45.2
Midgut NENs	143/49	31.3	25.7-NR
BP-NENs	50/31	17.6	13.6-NR
PPGLs	29/14	30.6	14.4-NR
Other GEP-NENs	57/26	32.8	18.7-NR
Other NGEP-NENs	37/18	21.0	11.1-NR

Abbreviations: N/n, sample/events; PFS, progression-free survival; CI, confidence interval; NR, not reached; pNEN, pancreatic neuroendocrine neoplasm; BP-NEN, bronchopulmonary neuroendocrine neoplasm; PPGL, pheochromocytoma and paraganglioma; NEN, neuroendocrine neoplasia: GEP, gastroenteropancreatic; NGEP, no gastroenteropancreatic.

Supplementary Materials, Annex Table 6B. Progression-free survival based on grade (WHO 2017).

Grade	N/n	Median PFS (months)	95% CI
NET G1	178/72	30.6	25.41-42.3
NET G2	292/136	21.3	19.30-31.6
NET G3	42/29	12.9	8.71-26.9
NEC G3	10/8	17.1	9.90-NR

Abbreviations: WHO, World Health Organization; N/n, sample/events; PFS, progression-free survival; CI, confidence interval; NET, neuroendocrine tumor; NEC, neuroendocrine carcinoma; NR, not reached

Supplementary Materials, Annex Table 6C. Progression-free survival determined by assessment method.

	N/n	Median PFS (months)	95% CI
[⁶⁸ Ga]Ga-DOTATOC, any Krenning	57/22	19.1	14.6-NR
SSTR scintigraphy, any Krenning	465/222	25.4	21.0-29.4
Logrank test, $\chi^2=0.5$ on 1 degrees of freedom, $p=0.5$			

Abbreviations: N/n, sample/events; PFS, progression-free survival; CI, confidence interval; NR, not reached; SSTRs: somatostatin receptors.

Supplementary Materials, Annex Table 6D. Progression-free survival determined by uptake intensity and assessment method.

	N/n	Median PFS (months)	95% CI
Any method + Krenning score 2	44/24	19.8	9.86-NR
[⁶⁸Ga]Ga-DOTATOC + Krenning score 3	34/13	19.7	14.7-NR
[⁶⁸Ga]Ga-DOTATOC + Krenning score 4	19/6	19.1	9.8-NR
SSTR scintigraphy + Krenning score 3	361/169	24.3	20.5-31.5
SSTR scintigraphy + Krenning score 4	64/32	28.3	21.3-49.2
Logrank test, $\chi^2= 2$ on 4 degrees of freedom, p= 0.7			

Abbreviations: N/n, sample/events; PFS, progression-free survival; CI, confidence interval; NR, not reached; SSTRs; somatostatin receptors.